Substrates for peptidase M08.001: leishmanolysin

Summary Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates

Peptide and protein substrates that are thought to be physiologically relevant are indicated by P. Peptide and protein substrates that are thought to be pathologically relevant are indicated by D. Peptide and protein substrates that are not physiologically relevant are indicated by N. Synthetic substrates are indicated by S. Click on the symbol to show only physiological, non-physiological or synthetic substrates, or here to display all substrates. How cleavage sites have been identified are indicated by the following evidence codes: NT = N-terminal sequencing, MS = mass spectroscopy, MU = mutation, CS = consensus sequence, LC = liquid chromatography. To see all annotated cleavages for a protein substrate, click on the UniProt Accession.

Substrate	Uniprot	Residue range	Cleavage Site	Cleavage type	Evidence	P4	P3	P2	P1	P1'	P2'	P3'	P4'	Reference	CutDB
complement C3	P01024	672-1663	peptide-Arg1320+Ser-peptide	N	AB	Ser	Leu	Leu	Arg	Ser	Glu	Glu	Thr	Brittingham et al.,2005
Complement C3 alpha chain	P01024	672-1663	peptide-Arg1303+Ser-peptide	N	AB	Leu	Pro	Ser	Arg	Ser	Ser	Lys	Ile	Brittingham et al.,2005
cytochrome {C} 81-104			Ile-Phe-Ala-Gly+Ile-Lys-Lys-Lys-Thr-Glu-Arg-Glu-Asp-Leu-Ile-Ala-Tyr-Leu-Lys-Lys-Ala-Thr-Asn-Glu	N		Ile	Phe	Ala	Gly	Ile	Lys	Lys	Lys	Bouvier, 2004
cytochrome {C} 81-104			Ile-Phe-Ala-Gly-Ile-Lys-Lys-Lys-Thr-Glu-Arg-Glu-Asp-Leu-Ile-Ala-Tyr+Leu-Lys-Lys-Ala-Thr-Asn-Glu	N		Leu	Ile	Ala	Tyr	Leu	Lys	Lys	Ala	Bouvier, 2004
cytochrome {C} 94-102Leu			Leu-Ile-Ala-Tyr+Leu-Lys-Lys-Ala-Thr	N		Leu	Ile	Ala	Tyr	Leu	Lys	Lys	Ala	Bouvier, 2004
cytochrome {C} 94-102Ser			Leu-Ile-Ala-Tyr+Ser-Lys-Lys-Ala-Thr	N		Leu	Ile	Ala	Tyr	Ser	Lys	Lys	Ala	Bouvier, 2004
dansyl-Ala-Tyr-Leu-Lys-Lys-Trp-Val-NH2			dansyl-Ala-Tyr+Leu-Lys-Lys-Trp-Val-NH2	S		-	Dns	Ala	Tyr	Leu	Lys	Lys	Trp	Bouvier, 2004
DObeta-HLA			Tyr-Arg+Leu-Gly-Ala-Pro-Phe-Thr-Gly-Val-Arg-Lys	N		-	-	Tyr	Arg	Leu	Gly	Ala	Pro	Bouvier, 2004
glucagon	P01274	53-81	His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr+Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr	N		Thr	Ser	Asp	Tyr	Ser	Lys	Tyr	Leu	Bouvier, 2004	16501
glucagon	P01274	53-81	His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp+Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr	N		Lys	Tyr	Leu	Asp	Ser	Arg	Arg	Ala	Bouvier, 2004	16502
glucagon	P01274	53-81	His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp+Leu-Met-Asn-Thr	N		Phe	Val	Gln	Trp	Leu	Met	Asn	Thr	Bouvier, 2004
HLA-CW3	Q29993	25-366	Leu-Arg-Arg-Tyr+Leu-Lys-Asn-Gly-Lys-Glu-Thr-Leu-Gln-Arg-Ala	N		Leu	Arg	Arg	Tyr	Leu	Lys	Asn	Gly	Bouvier, 2004
HLA-CW3	Q29993	25-366	Leu-Arg-Arg-Tyr-Leu-Lys+Asn-Gly-Lys-Glu-Thr-Leu-Gln-Arg-Ala	N		Arg	Tyr	Leu	Lys	Asn	Gly	Lys	Glu	Bouvier, 2004
insulin B-chain (oxidized)	P01317	25-54	Phe-Val-Asn-Gln-His-Leu-Cya-Gly+Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cya-Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Ala	N		His	Leu	Cya	Gly	Ser	His	Leu	Val	Bouvier, 2004
insulin B-chain (oxidized)	P01317	25-54	Phe-Val-Asn-Gln-His-Leu-Cya-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Tyr+Leu-Val-Cya-Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Ala	N		Glu	Ala	Leu	Tyr	Leu	Val	Cya	Gly	Bouvier, 2004
leishmanolysin	P08148	40-577	peptide-Val100+Val-peptide	P		Ala	Arg	Ser	Val	Val	Arg	Asp	Val	Bouvier, 2004	16506
leishmanolysin precursor cleavage site peptide	P08148	97-105	Ala-Arg-Ser-Val+Val-Arg-Asp-Val-Asn	P		Ala	Arg	Ser	Val	Val	Arg	Asp	Val	Bouvier, 2004
MARCKS-like protein	P28667	2-220	peptide-Ser93+Phe-peptide	P		Lys	Lys	Phe	Ser	Phe	Lys	Lys	Pro	Corradin et al., 1999	16508
multidrug resistance-associated protein 1	P33527	1-1531	peptide-Ser92+Phe-peptide	N		Leu	Phe	Tyr	Ser	Phe	Trp	Glu	Arg	Bouvier, 2004
VSG peptide 36			Ala-Lys-Asp-Ser-Ser-Ile-Leu-Val+Thr-Lys-Lys-Phe-Ala	N		Ser	Ile	Leu	Val	Thr	Lys	Lys	Phe	Bouvier, 2004